Testing and Treatment Patterns Rapidly Changing in CLL
Testing patterns associated with the diagnosis and treatment of chronic lymphocytic leukemia have changed rapidly during the last decade. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2018 Category: American Health Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib Alone for Older Patients With Untreated CLL
Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine – rituximab combination for older patients with chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

For Chronic Leukemia Patients, the News Just Got Even Better
Several chronic lymphocytic leukemia (CLL) patients at the Wilmot Cancer Institute took part in two groundbreaking, nationwide phase 3 studies that are changing the way doctors treat the disease. The positive results are being reported this weekend at the 2018 American Society of Hematology (ASH) annual meeting — and will immediately impact CLL patients in the Rochester region and across the U.S., said Paul Barr, M.D., director of Wilmot’s Clinical Trials Office. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 29, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a s... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

NICE rejects AbbVie leukemia drug over price
NICE gave a negative opinion on AbbVie ’s Venclyxta in combination with Roche’s Rituxan, for treating relapsed or refractory chronic lymphocytic leukaemia in adults. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 26, 2018 Category: Pharmaceuticals Source Type: news

Researchers in Barcelona awarded with one of the most prestigious EU grants to unravel CLL
(Center for Genomic Regulation) The European Research Council today announced the results of the 2018 ERC Synergy Grants Call. A project, the BCLL@las, of four research groups from the Centro Nacional de An á lisis Gen ó mico of the Centre for Genomic Regulation, and the Institut d'Investigacions Biom è diques August Pi i Sunyer have received this prestigious grant to unravel the genomics and epigenomics of chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2018 Category: Cancer & Oncology Source Type: news

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which sho... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, obinutuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2018 Category: Pharmaceuticals Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
Duvelisib extended progression - free survival to 13.3 months versus 9.9 months for ofatumumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 10, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
WEDNESDAY, Oct. 10, 2018 -- For patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the oral, dual inhibitor of phosphoinositide 3-kinase- δ and -γ, duvelisib, seems effective, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2018 Category: Pharmaceuticals Source Type: news

MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicin
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma
(American Society of Hematology) For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to the study, duvelisib extended PFS from a median of 9.9 months on ofatumumab to 13.3 months. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Duvelisib Approved for Certain Lymphomas Duvelisib Approved for Certain Lymphomas
The FDA approved the new drug for use in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 24, 2018 Category: Drugs & Pharmacology Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

Critically Elevated Potassium in Chronic Lymphocytic Leukemia Critically Elevated Potassium in Chronic Lymphocytic Leukemia
A misdiagnosis as to the cause of hyperkalemia in this patient led to unnecessary dialysis, demonstrating the need to be alert to potentially false potassium results in patients with elevated WBC counts.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Stress linked to more advanced disease in some leukemia patients
(Ohio State University) Patients with chronic lymphocytic leukemia (CLL) who feel more stress also have more cancer cells in their blood and elevated levels of three other markers of more advanced disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2018 Category: Cancer & Oncology Source Type: news

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring
While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - August 14, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Medical News Today: What is the outlook for chronic lymphocytic leukemia?
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Although doctors can very rarely cure CLL, survival rates for this cancer are typically good. A person ’s life expectancy for CLL depends on how far the cancer has progressed and when they receive treatment. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

Melanoma linked with CLL, close monitoring recommended
(University of Rochester Medical Center) While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2018 Category: International Medicine & Public Health Source Type: news

Mutations in Half of Patients With CLL Who Relapse on Ibrutinib Mutations in Half of Patients With CLL Who Relapse on Ibrutinib
Acquired mutations were present in 50% of patients with chronic lymphocytic leukemia (CLL) who relapsed after treatment with ibrutinib (Imbruvica).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Survival Longer With Obinutuzumab Compared to Rituximab in CLL Survival Longer With Obinutuzumab Compared to Rituximab in CLL
New longer-term results with overall survival data confirm the superiority of the newer agent over the earlier-generation anti-CD20 drug rituximab for previously untreated chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 20, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1] uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news

The cancer revolution: How you can benefit from a new test which could mean no more chemo
Mike Brandon, 34, from Bristol was diagnosed with chronic lymphocytic leukaemia which is deemed untreatable in the UK but he was able to undergo specialised life-saving therapy in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - June 10, 2018 Category: Consumer Health News Source Type: news

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA -- June 8, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Rituxan ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2018 Category: Drugs & Pharmacology Source Type: news

Ibrutinib Plus Venetoclax Shows Promising Activity Against CLL
Bryant FurlowJun 4, 2018In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Phase I trial finds experimental drug safe in treating chronic lymphocytic leukemia
(University of California - San Diego) Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the 'stemness' of chronic leukemia cancer (CLL) cells -- their ability to self-renew and resist terminal differentiation and senescence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

CLL patient treated at Penn goes into remission thanks to single CAR T cell
(University of Pennsylvania School of Medicine) Researchers at the University of Pennsylvania's Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed cancer free in the five years since, with CAR T cells still present in his immune system. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2018 Category: Cancer & Oncology Source Type: news

IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Phase 3 iLLUMINATE trial met primary endpoint of progression-free survival (PFS) in patients with previously untreated CLL and Small Lymphocytic Lymphoma (SLL) compared to chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC) ... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, GAZYVA, obinutuzumab, Chronic Lymphocytic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2018 Category: Pharmaceuticals Source Type: news

After 6-month wait, cheques land on doorstep of sick Ontario worker
Mitch LaPrade has been fighting the WSIB for 11 years, arguing his chronic lymphocytic leukemia (CLL) was caused by exposure to a carcinogen called benzene. The highest level of Ontario’s workers’ compensation system ruled in his favour last fall, but his cheques only arrived this week after a CBC investigation. (Source: CBC | Health)
Source: CBC | Health - May 11, 2018 Category: Consumer Health News Tags: News/Canada Source Type: news

Lymphoma, Leukemia Survivors Have Increased Health Care Use
WEDNESDAY, May 9, 2018 -- Survivors of lymphoma and chronic lymphocytic leukemia (CLL) have increased use of health care services versus a normative population, according to a study published online April 26 in Cancer. Lindy P.J. Arts, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 9, 2018 Category: Pharmaceuticals Source Type: news

Biomarker predicts benefit from immunotherapy
Researchers found a biomarker that, if confirmed, could be used to identify which people with chronic lymphocytic leukemia would benefit from CAR T-cell therapy. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 8, 2018 Category: Consumer Health News Source Type: news

T cell biomarker predicts which CLL patients will respond to CAR T cell therapy
(University of Pennsylvania School of Medicine) Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2018 Category: International Medicine & Public Health Source Type: news

Interim MRD May Help Direct Individual Treatment for CLL
Achieving undetectable MRD after chemoimmunotherapy predicted longer progression-free and overall survival in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - April 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news

Duvelisib Granted Priority Review for R/R CLL/SLL and FL
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Follicular Lymphoma Hematologic Malignancies News Source Type: news